Results 131 to 140 of about 692,682 (292)
Diabetic Medicine, Volume 43, Issue 2, February 2026.Abstract Aim Type 2 diabetes (T2D) in pregnancy is increasingly common and associated with suboptimal outcomes for these women and their children. We aimed to synthesize observational evidence on associations of modifiable preconception, pregnancy and postpartum risk factors with perinatal outcomes among women with pregestational T2D.
Danielle Schoenaker +11 more
wiley +1 more source
Diabetes, obesity and metabolism, 2019 To compare glycaemic control, hypoglycaemia and treatment discontinuation of insulin glargine 300 units/mL (Gla‐300) and insulin degludec (IDeg) in a real‐world study of insulin‐naïve adults with type 2 diabetes (T2D).
S. Sullivan +8 more
semanticscholar +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1036-1048, February 2026.Abstract Aims To evaluate the effectiveness and safety of early initiation of subcutaneous (SC) basal insulin in combination with intravenous insulin infusion (IVII), compared with IVII alone, for the management of diabetic ketoacidosis (DKA). Materials and Methods A systematic search of PubMed, Embase, Scopus, and the Cochrane Library was conducted to
Kitti Thammakosol +4 more
wiley +1 more source
Insulin Glargine in the Intensive Care Unit: A Model-Based Clinical Trial Design [PDF]
, 2005 Online 4 Oct 2012Introduction: Current succesful AGC (Accurate Glycemic Control) protocols require extra clinical effort and are impractical in less acute wards where patients are still susceptible to stress-induced hyperglycemia.
B. Hollunder +43 more
core +3 more sources
Diabetes, obesity and metabolism, 2019 To compare HbA1c and hypoglycaemia in insulin‐naïve patients with type 2 diabetes (T2D) who initiated insulin glargine 300 units/mL (Gla‐300) or 100 units/mL (Gla‐100).
T. Bailey +6 more
semanticscholar +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo +8 more
wiley +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2011 Shinya Abe1,2, Gaku Inoue1,2, Satoru Yamada1,3, Junichiro Irie1,3, Hiroyuki Nojima2, Kaoru Tsuyusaki2, Kensuke Usui2, Koichiro Atsuda2, Toshikazu Yamanouchi41Diabetes Center, Kitasato Institute Hospital, 2Center for Clinical Pharmacy and Clinical ...
Abe S +8 more
doaj
Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources [PDF]
, 2016 Aims: To assess resource utilization associated with severe hypoglycaemia across three insulin regimens in a large phase 3a clinical programme involving people with Type 1 diabetes treated with basal–bolus insulin, people with Type 2 diabetes treated ...
Akram +44 more
core +1 more source
Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration [PDF]
, 2023 Víctor Enrique Sarmiento-Ortega +5 more
openalex +1 more source
Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1350-1358, February 2026.Abstract Aims To evaluate treatment‐emergent antidrug antibodies (TE ADA) in once‐weekly basal insulin efsitora‐treated participants with type 1 and type 2 diabetes mellitus (T1DM and T2DM) from 5 phase 3 clinical trials and their potential impact on pharmacokinetics, efficacy and safety.
Yun Wang +8 more
wiley +1 more source